Roivant swings to Q3 loss as revenue drops

Reuters02-06

Roivant swings to Q3 loss as revenue drops

Overview

Biopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-ago
Posts Q4 net loss vs profit in year-ago quarter
Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Outlook

Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026
Company expects topline data from brepocitinib NIU trial in second half of 2026
Roivant actively exploring additional indications for brepocitinib

Result Drivers

R&D EXPENSES - Increase in R&D expenses driven by program-specific costs and share-based compensation
STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$2 mln
Q3 EPS		-$0.38
Q3 Net Income		-$313.70 mln
Q3 Income From Operations	Miss	-$339.15 mln	-$306.38 mln (6 Analysts)
Q3 Operating Expenses		$341.15 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14

Press Release: ID:nGNX547nb2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609598134?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609598134","market":"nz","top_or_hot":-1,"title":"Roivant swings to Q3 loss as revenue drops","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Roivant swings to Q3 loss as revenue drops</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-ago</p></li><li><p>Posts Q4 net loss vs profit in year-ago quarter</p></li><li><p>Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026</p></li><li><p>Company expects topline data from brepocitinib NIU trial in second half of 2026</p></li><li><p>Roivant actively exploring additional indications for brepocitinib</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses driven by program-specific costs and share-based compensation</p></li><li><p>STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$2 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.38</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$313.70 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$339.15 mln</p></td><td><p>-$306.38 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$341.15 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14</p></li></ul><p>Press Release: <span>ID:nGNX547nb2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roivant swings to Q3 loss as revenue drops</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoivant swings to Q3 loss as revenue drops\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Roivant swings to Q3 loss as revenue drops</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-ago</p></li><li><p>Posts Q4 net loss vs profit in year-ago quarter</p></li><li><p>Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026</p></li><li><p>Company expects topline data from brepocitinib NIU trial in second half of 2026</p></li><li><p>Roivant actively exploring additional indications for brepocitinib</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses driven by program-specific costs and share-based compensation</p></li><li><p>STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$2 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.38</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$313.70 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td><p>Miss</p></td><td><p>-$339.15 mln</p></td><td><p>-$306.38 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$341.15 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14</p></li></ul><p>Press Release: <span>ID:nGNX547nb2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL1N3Z20K4:1","article_id":"2609598134","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609598134","pubTimestamp":1770379936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Roivant swings to Q3 loss as revenue dropsOverviewBiopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-agoPosts Q4 net loss vs profit in year-ago quarterRoivant reported $4.5 bln in cash","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"由于收入下降，Roivant第三季度出现亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":0.9},"content_text":"Roivant swings to Q3 loss as revenue dropsOverviewBiopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-agoPosts Q4 net loss vs profit in year-ago quarterRoivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025OutlookRoivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026Company expects topline data from brepocitinib NIU trial in second half of 2026Roivant actively exploring additional indications for brepocitinibResult DriversR&D EXPENSES - Increase in R&D expenses driven by program-specific costs and share-based compensationSTRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$2 mlnQ3 EPS-$0.38Q3 Net Income-$313.70 mlnQ3 Income From OperationsMiss-$339.15 mln-$306.38 mln (6 Analysts)Q3 Operating Expenses$341.15 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14Press Release: ID:nGNX547nb2For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609598134","isCrawlerRequest":true}